Medical Cannabis Advocacy in the Middle East During the 1960s

Setting the scene: cannabis in the region before 1960

Hashish had been part of Middle Eastern and North African culture for centuries, with Lebanon's Bekaa Valley and parts of Egypt being well-known production zones. By the early 20th century, however, regional governments had moved decisively against it. Egypt was one of the most aggressive prohibitionists internationally, having lobbied the League of Nations to add cannabis to controlled substances lists in the 1920s Strong evidence^[1]. By 1961, cannabis was placed in the most restrictive schedules of the UN Single Convention on Narcotic Drugs, a treaty most Middle Eastern states signed ^[2]. So the 1960s opened with cannabis already framed regionally as a vice and a policing problem, not a medicine.

What actually happened: the Mechoulam program in Israel

The single most consequential 1960s cannabis story in the Middle East is scientific, not activist. In 1963, Raphael Mechoulam and Yuval Shvo, working at the Weizmann Institute in Rehovot, published the structure of cannabidiol (CBD) ^[3]. In 1964, Mechoulam and Yechiel Gaoni isolated and characterized Δ⁹-tetrahydrocannabinol (THC), identifying it as the principal psychoactive constituent of cannabis Strong evidence^[4]. The hashish they worked with came from a five-kilogram block obtained from the Israeli national police, a provenance Mechoulam himself documented in later interviews and memoirs ^[5]. Throughout the decade, Mechoulam's group also clarified the structures of other cannabinoids and began animal pharmacology in collaboration with Habib Edery and others. This was basic chemistry and pharmacology, not clinical advocacy — but it laid the groundwork every later medical-cannabis program would build on.

Was there 'advocacy'? Mostly no — with caveats

If by 'advocacy' we mean organized public campaigns to legalize or normalize medical cannabis, the 1960s Middle East had essentially none Strong evidence. Egypt's official position remained strongly prohibitionist; Lebanon's government periodically attempted to eradicate Bekaa cultivation; Iran (often grouped with the region in this era) executed drug traffickers under the Shah's narcotics laws. What did exist were quieter forms of professional interest:

• Scientific curiosity: Mechoulam's team in Israel openly framed their work as medically motivated, arguing in print that morphine and cocaine had been isolated from their source plants over a century earlier and that cannabis deserved the same chemical attention ^[4].
• Clinician observations: Egyptian and Lebanese psychiatrists published case reports on hashish use, mostly framing it as a harm rather than a therapy. The often-cited work of Soueif in Egypt, beginning in the late 1960s, was a study of cognitive effects in chronic users, not an advocacy project ^[6].
• Informal medical use: Folk and traditional medicine use of cannabis preparations continued in rural areas, but this was customary practice, not organized advocacy Weak / limited.

How the myth grew

Modern cannabis media sometimes presents the 1960s Middle East as a golden age of medical-cannabis enlightenment. This is largely retrospective storytelling, shaped by three factors:

1. Mechoulam's later fame. Once Israel became a leading medical-cannabis research and export country in the 2000s and 2010s, journalists projected that prominence backwards onto the 1960s ^[7]. The science was real; the surrounding 'movement' was not.
2. Conflation with Western counterculture. Lebanese 'Red' and 'Blonde' hashish became iconic in 1960s European and American drug culture, which retroactively glamorized Middle Eastern production as a kind of tacit endorsement. The producers themselves were farmers and smugglers, not advocates Anecdote.
3. Romanticized readings of traditional medicine. Older Arabic and Persian medical texts do reference cannabis (qinnab, bhang), and these sometimes get cited as if they represented a living 1960s medical tradition. They did not in any organized clinical sense Disputed^[8].

Timeline of documented events

• 1961: UN Single Convention on Narcotic Drugs places cannabis in Schedules I and IV. Most Middle Eastern states sign or accede ^[2].
• 1963: Mechoulam and Shvo publish the structure of CBD ^[3].
• 1964: Gaoni and Mechoulam publish the isolation and structure of Δ⁹-THC in the Journal of the American Chemical Society ^[4].
• Mid-1960s: Lebanese government conducts intermittent eradication campaigns in the Bekaa, with limited success ^[9].
• 1967: Mechoulam's group reports synthesis of THC, enabling broader pharmacological study ^[10].
• Late 1960s: M. I. Soueif begins systematic studies of chronic hashish users in Egyptian prisons, published into the 1970s ^[6].

What's fair to conclude

The honest historical picture is this: the 1960s Middle East was the birthplace of modern cannabinoid chemistry, almost entirely through the work of one Israeli laboratory operating with material supplied by police. It was not the birthplace of a medical cannabis advocacy movement. That kind of organized advocacy is largely a phenomenon of the 1990s and later, in places like the United States, Canada, the Netherlands, and — eventually — Israel itself. Anyone who tells you otherwise is selling a tidier story than the evidence supports.

Sources

How this page was made